Category Archives: Regenerative Medicine

Los Angeles, United State- The global Human Embryonic Stem Cells (HESC) market is carefully researched in the report while largely concentrating on top players and their business tactics, geographical expansion, market segments, competitive landscape, manufacturing, and pricing and cost structures. Each section of the research study is specially prepared to explore key aspects of the global Human Embryonic Stem Cells (HESC) market. For instance, the market dynamics section digs deep into the drivers, restraints, trends, and opportunities of the global Human Embryonic Stem Cells (HESC) Market. With qualitative and quantitative analysis, we help you with thorough and comprehensive research on the global Human Embryonic Stem Cells (HESC) market. We have also focused on SWOT, PESTLE, and Porters Five Forces analyses of the global Human Embryonic Stem Cells (HESC) market.

Leading players of the global Human Embryonic Stem Cells (HESC) market are analyzed taking into account their market share, recent developments, new product launches, partnerships, mergers or acquisitions, and markets served. We also provide an exhaustive analysis of their product portfolios to explore the products and applications they concentrate on when operating in the global Human Embryonic Stem Cells (HESC) market. Furthermore, the report offers two separate market forecasts one for the production side and another for the consumption side of the global Human Embryonic Stem Cells (HESC) market. It also provides useful recommendations for new as well as established players of the global Human Embryonic Stem Cells (HESC) market.

Get PDF Sample Copy of the Report to understand the structure of the complete report: (Including Full TOC, List of Tables & Figures, Chart) :https://www.qyresearch.com/sample-form/form/1749373/covid-19-impact-on-human-embryonic-stem-cells-hesc-market

Human Embryonic Stem Cells (HESC) Market Leading Players

ESI BIO, Thermo Fisher, BioTime, MilliporeSigma, BD Biosciences, Astellas Institute of Regenerative Medicine, Asterias Biotherapeutics, Cell Cure Neurosciences, PerkinElmer, Takara Bio, Cellular Dynamics International, Reliance Life Sciences, Research & Diagnostics Systems, SABiosciences, STEMCELL Technologies, Stemina Biomarker Discovery, Takara Bio, TATAA Biocenter, UK Stem Cell Bank, ViaCyte, Vitrolife, etc.

Human Embryonic Stem Cells (HESC) Segmentation by Product

, Totipotent Stem Cells, Pluripotent Stem Cells, Unipotent Stem Cells

Human Embryonic Stem Cells (HESC) Segmentation by Application

, Research, Clinical Trials, Others

Report Objectives

Analyzing the size of the global Human Embryonic Stem Cells (HESC) market on the basis of value and volume.

Accurately calculating the market shares, consumption, and other vital factors of different segments of the global Human Embryonic Stem Cells (HESC) market.

Exploring the key dynamics of the global Human Embryonic Stem Cells (HESC) market.

Highlighting important trends of the global Human Embryonic Stem Cells (HESC) market in terms of production, revenue, and sales.

Deeply profiling top players of the global Human Embryonic Stem Cells (HESC) market and showing how they compete in the industry.

Studying manufacturing processes and costs, product pricing, and various trends related to them.

Showing the performance of different regions and countries in the global Human Embryonic Stem Cells (HESC) market.

Forecasting the market size and share of all segments, regions, and the global market.

Get Full report in your inbox within 24 hours at USD (3250) :https://www.qyresearch.com/settlement/pre/08101371beb1ead901ab2ea442a36625,0,1,covid-19-impact-on-human-embryonic-stem-cells-hesc-market

Table of Contents.

1.1 Research Scope1.2 Market Segmentation1.3 Research Objectives1.4 Research Methodology1.4.1 Research Process1.4.2 Data Triangulation1.4.3 Research Approach1.4.4 Base Year1.5 Coronavirus Disease 2019 (Covid-19) Impact Will Have a Severe Impact on Global Growth1.5.1 Covid-19 Impact: Global GDP Growth, 2019, 2020 and 2021 Projections1.5.2 Covid-19 Impact: Commodity Prices Indices1.5.3 Covid-19 Impact: Global Major Government Policy1.6 The Covid-19 Impact on Human Embryonic Stem Cells (HESC) Industry1.7 COVID-19 Impact: Human Embryonic Stem Cells (HESC) Market Trends 2 Global Human Embryonic Stem Cells (HESC) Quarterly Market Size Analysis2.1 Human Embryonic Stem Cells (HESC) Business Impact Assessment COVID-192.1.1 Global Human Embryonic Stem Cells (HESC) Market Size, Pre-COVID-19 and Post- COVID-19 Comparison, 2015-20262.1.2 Global Human Embryonic Stem Cells (HESC) Price, Pre-COVID-19 and Post- COVID-19 Comparison, 2015-20262.2 Global Human Embryonic Stem Cells (HESC) Quarterly Market Size 2020-20212.3 COVID-19-Driven Market Dynamics and Factor Analysis2.3.1 Drivers2.3.2 Restraints2.3.3 Opportunities2.3.4 Challenges 3 Quarterly Competitive Assessment, 20203.1 Global Human Embryonic Stem Cells (HESC) Quarterly Market Size by Manufacturers, 2019 VS 20203.2 Global Human Embryonic Stem Cells (HESC) Factory Price by Manufacturers3.3 Location of Key Manufacturers Human Embryonic Stem Cells (HESC) Manufacturing Factories and Area Served3.4 Date of Key Manufacturers Enter into Human Embryonic Stem Cells (HESC) Market3.5 Key Manufacturers Human Embryonic Stem Cells (HESC) Product Offered3.6 Mergers & Acquisitions, Expansion Plans 4 Impact of Covid-19 on Human Embryonic Stem Cells (HESC) Segments, By Type4.1 Introduction1.4.1 Totipotent Stem Cells1.4.2 Pluripotent Stem Cells1.4.3 Unipotent Stem Cells4.2 By Type, Global Human Embryonic Stem Cells (HESC) Market Size, 2019-20214.2.1 By Type, Global Human Embryonic Stem Cells (HESC) Market Size by Type, 2020-20214.2.2 By Type, Global Human Embryonic Stem Cells (HESC) Price, 2020-2021 5 Impact of Covid-19 on Human Embryonic Stem Cells (HESC) Segments, By Application5.1 Overview5.5.1 Research5.5.2 Clinical Trials5.5.3 Others5.2 By Application, Global Human Embryonic Stem Cells (HESC) Market Size, 2019-20215.2.1 By Application, Global Human Embryonic Stem Cells (HESC) Market Size by Application, 2019-20215.2.2 By Application, Global Human Embryonic Stem Cells (HESC) Price, 2020-2021 6 Geographic Analysis6.1 Introduction6.2 North America6.2.1 Macroeconomic Indicators of US6.2.2 US6.2.3 Canada6.3 Europe6.3.1 Macroeconomic Indicators of Europe6.3.2 Germany6.3.3 France6.3.4 UK6.3.5 Italy6.4 Asia-Pacific6.4.1 Macroeconomic Indicators of Asia-Pacific6.4.2 China6.4.3 Japan6.4.4 South Korea6.4.5 India6.4.6 ASEAN6.5 Rest of World6.5.1 Latin America6.5.2 Middle East and Africa 7 Company Profiles7.1 ESI BIO7.1.1 ESI BIO Business Overview7.1.2 ESI BIO Human Embryonic Stem Cells (HESC) Quarterly Production and Revenue, 20207.1.3 ESI BIO Human Embryonic Stem Cells (HESC) Product Introduction7.1.4 ESI BIO Response to COVID-19 and Related Developments7.2 Thermo Fisher7.2.1 Thermo Fisher Business Overview7.2.2 Thermo Fisher Human Embryonic Stem Cells (HESC) Quarterly Production and Revenue, 20207.2.3 Thermo Fisher Human Embryonic Stem Cells (HESC) Product Introduction7.2.4 Thermo Fisher Response to COVID-19 and Related Developments7.3 BioTime7.3.1 BioTime Business Overview7.3.2 BioTime Human Embryonic Stem Cells (HESC) Quarterly Production and Revenue, 20207.3.3 BioTime Human Embryonic Stem Cells (HESC) Product Introduction7.3.4 BioTime Response to COVID-19 and Related Developments7.4 MilliporeSigma7.4.1 MilliporeSigma Business Overview7.4.2 MilliporeSigma Human Embryonic Stem Cells (HESC) Quarterly Production and Revenue, 20207.4.3 MilliporeSigma Human Embryonic Stem Cells (HESC) Product Introduction7.4.4 MilliporeSigma Response to COVID-19 and Related Developments7.5 BD Biosciences7.5.1 BD Biosciences Business Overview7.5.2 BD Biosciences Human Embryonic Stem Cells (HESC) Quarterly Production and Revenue, 20207.5.3 BD Biosciences Human Embryonic Stem Cells (HESC) Product Introduction7.5.4 BD Biosciences Response to COVID-19 and Related Developments7.6 Astellas Institute of Regenerative Medicine7.6.1 Astellas Institute of Regenerative Medicine Business Overview7.6.2 Astellas Institute of Regenerative Medicine Human Embryonic Stem Cells (HESC) Quarterly Production and Revenue, 20207.6.3 Astellas Institute of Regenerative Medicine Human Embryonic Stem Cells (HESC) Product Introduction7.6.4 Astellas Institute of Regenerative Medicine Response to COVID-19 and Related Developments7.7 Asterias Biotherapeutics7.7.1 Asterias Biotherapeutics Business Overview7.7.2 Asterias Biotherapeutics Human Embryonic Stem Cells (HESC) Quarterly Production and Revenue, 20207.7.3 Asterias Biotherapeutics Human Embryonic Stem Cells (HESC) Product Introduction7.7.4 Asterias Biotherapeutics Response to COVID-19 and Related Developments7.8 Cell Cure Neurosciences7.8.1 Cell Cure Neurosciences Business Overview7.8.2 Cell Cure Neurosciences Human Embryonic Stem Cells (HESC) Quarterly Production and Revenue, 20207.8.3 Cell Cure Neurosciences Human Embryonic Stem Cells (HESC) Product Introduction7.8.4 Cell Cure Neurosciences Response to COVID-19 and Related Developments7.9 PerkinElmer7.9.1 PerkinElmer Business Overview7.9.2 PerkinElmer Human Embryonic Stem Cells (HESC) Quarterly Production and Revenue, 20207.9.3 PerkinElmer Human Embryonic Stem Cells (HESC) Product Introduction7.9.4 PerkinElmer Response to COVID-19 and Related Developments7.10 Takara Bio7.10.1 Takara Bio Business Overview7.10.2 Takara Bio Human Embryonic Stem Cells (HESC) Quarterly Production and Revenue, 20207.10.3 Takara Bio Human Embryonic Stem Cells (HESC) Product Introduction7.10.4 Takara Bio Response to COVID-19 and Related Developments7.11 Cellular Dynamics International7.11.1 Cellular Dynamics International Business Overview7.11.2 Cellular Dynamics International Human Embryonic Stem Cells (HESC) Quarterly Production and Revenue, 20207.11.3 Cellular Dynamics International Human Embryonic Stem Cells (HESC) Product Introduction7.11.4 Cellular Dynamics International Response to COVID-19 and Related Developments7.12 Reliance Life Sciences7.12.1 Reliance Life Sciences Business Overview7.12.2 Reliance Life Sciences Human Embryonic Stem Cells (HESC) Quarterly Production and Revenue, 20207.12.3 Reliance Life Sciences Human Embryonic Stem Cells (HESC) Product Introduction7.12.4 Reliance Life Sciences Response to COVID-19 and Related Developments7.13 Research & Diagnostics Systems7.13.1 Research & Diagnostics Systems Business Overview7.13.2 Research & Diagnostics Systems Human Embryonic Stem Cells (HESC) Quarterly Production and Revenue, 20207.13.3 Research & Diagnostics Systems Human Embryonic Stem Cells (HESC) Product Introduction7.13.4 Research & Diagnostics Systems Response to COVID-19 and Related Developments7.14 SABiosciences7.14.1 SABiosciences Business Overview7.14.2 SABiosciences Human Embryonic Stem Cells (HESC) Quarterly Production and Revenue, 20207.14.3 SABiosciences Human Embryonic Stem Cells (HESC) Product Introduction7.14.4 SABiosciences Response to COVID-19 and Related Developments7.15 STEMCELL Technologies7.15.1 STEMCELL Technologies Business Overview7.15.2 STEMCELL Technologies Human Embryonic Stem Cells (HESC) Quarterly Production and Revenue, 20207.15.3 STEMCELL Technologies Human Embryonic Stem Cells (HESC) Product Introduction7.15.4 STEMCELL Technologies Response to COVID-19 and Related Developments7.16 Stemina Biomarker Discovery7.16.1 Stemina Biomarker Discovery Business Overview7.16.2 Stemina Biomarker Discovery Human Embryonic Stem Cells (HESC) Quarterly Production and Revenue, 20207.16.3 Stemina Biomarker Discovery Human Embryonic Stem Cells (HESC) Product Introduction7.16.4 Stemina Biomarker Discovery Response to COVID-19 and Related Developments7.17 Takara Bio7.17.1 Takara Bio Business Overview7.17.2 Takara Bio Human Embryonic Stem Cells (HESC) Quarterly Production and Revenue, 20207.17.3 Takara Bio Human Embryonic Stem Cells (HESC) Product Introduction7.17.4 Takara Bio Response to COVID-19 and Related Developments7.18 TATAA Biocenter7.18.1 TATAA Biocenter Business Overview7.18.2 TATAA Biocenter Human Embryonic Stem Cells (HESC) Quarterly Production and Revenue, 20207.18.3 TATAA Biocenter Human Embryonic Stem Cells (HESC) Product Introduction7.18.4 TATAA Biocenter Response to COVID-19 and Related Developments7.19 UK Stem Cell Bank7.19.1 UK Stem Cell Bank Business Overview7.19.2 UK Stem Cell Bank Human Embryonic Stem Cells (HESC) Quarterly Production and Revenue, 20207.19.3 UK Stem Cell Bank Human Embryonic Stem Cells (HESC) Product Introduction7.19.4 UK Stem Cell Bank Response to COVID-19 and Related Developments7.20 ViaCyte7.20.1 ViaCyte Business Overview7.20.2 ViaCyte Human Embryonic Stem Cells (HESC) Quarterly Production and Revenue, 20207.20.3 ViaCyte Human Embryonic Stem Cells (HESC) Product Introduction7.20.4 ViaCyte Response to COVID-19 and Related Developments7.21 Vitrolife7.21.1 Vitrolife Business Overview7.21.2 Vitrolife Human Embryonic Stem Cells (HESC) Quarterly Production and Revenue, 20207.21.3 Vitrolife Human Embryonic Stem Cells (HESC) Product Introduction7.21.4 Vitrolife Response to COVID-19 and Related Developments 8 Supply Chain and Sales Channels Analysis8.1 Human Embryonic Stem Cells (HESC) Supply Chain Analysis8.1.1 Human Embryonic Stem Cells (HESC) Supply Chain Analysis8.1.2 Covid-19 Impact on Human Embryonic Stem Cells (HESC) Supply Chain8.2 Distribution Channels Analysis8.2.1 Human Embryonic Stem Cells (HESC) Distribution Channels8.2.2 Covid-19 Impact on Human Embryonic Stem Cells (HESC) Distribution Channels8.2.3 Human Embryonic Stem Cells (HESC) Distributors8.3 Human Embryonic Stem Cells (HESC) Customers 9 Key Findings 10 Appendix10.1 About Us10.2 Disclaimer

About Us:

QYResearch always pursuits high product quality with the belief that quality is the soul of business. Through years of effort and supports from the huge number of customer supports, QYResearch consulting group has accumulated creative design methods on many high-quality markets investigation and research team with rich experience. Today, QYResearch has become a brand of quality assurance in the consulting industry.

Read the original post:
Human Embryonic Stem Cells (HESC) Market 2020 Global Share, Growth, Size, Opportunities, Trends, Regional Overview, Leading Company Analysis, And Key...

Dr. Timothy Chan, an immuno-oncology and cancer genomics expert, has been named director of the Center for Immunotherapy and Precision Immuno-Oncology at Cleveland Clinic, according to a news release.

He will lead the new center, which brings together multidisciplinary experts from across the system to advance research and treatment related to immuno-oncology, a rapidly growing field.

"Immunotherapy is the future of research in cancer and various other diseases and Cleveland Clinic has made it a priority by establishing this new center," Dr. Serpil Erzurum, chair of the Clinic's Lerner Research Institute, said in a prepared statement. "The Center for Immunotherapy and Precision Immuno-Oncology will empower clinicians and scientists throughout the enterprise to advance personalized cancer care and breakthrough immunotherapy research at Cleveland Clinic."

The center, which opened this month with the arrival of Chan, was approved in 2019.

Chan joins the system from Memorial Sloan Kettering Cancer Center and Weill Cornell School of Medicine, where he led the Immunogenomics and Precision Oncology Platform and was a tenured professor, the PaineWebber Chair and the Translational Oncology Division chair, according to the release, which notes he is a pioneer in using genomics to determine which patients will respond best to certain types of immunotherapies. He also joins the leadership of the National Center for Regenerative Medicine of Case Western Reserve University and is on staff in the Genomic Medicine Institute of the Lerner Research Institute and the Department of Radiation Oncology of the Taussig Cancer Institute, according to the release.

The Center for Immunotherapy and Precision Immuno-Oncology will have four arms: a Cleveland cell therapy program in collaboration with the Case Comprehensive Cancer Center; immunologic medicine and immuno-oncology labs; a precision immuno-oncology program; and a precision immuno-oncology and developmental therapeutics program.

The center will recruit experts from around the country and globe who specialize in computational science, immunotherapy and cancer immunology, according to the release.

Initially, the new center will have sites focused on immunotherapy research and developmental therapeutics in both Cleveland and the Cleveland Clinic Florida Research and Innovation Center, a 107,000-square-foot laboratory and office space slated to open this summer in Port St. Lucie, Fla. Chan will also collaborate with experts in the new Center for Global and Emerging Pathogens, which was announced last week after a year and a half of planning. This center looks to broaden the understanding of emerging pathogens (from Zika virus to SARS-CoV-2, which causes COVID-19) and expedite critically needed treatments and vaccines.

"Innovation in precision immunotherapy is one of the most exciting areas in cancer research," said Dr. Brian Bolwell, chairman of Taussig Cancer Institute, Cleveland Clinic Cancer Center, in a prepared statement. "The addition of Dr. Chan, a pioneer in cancer genomics, and the new center's focus on research and clinical trials will strengthen our ability to provide advanced treatment options for our patients."

Board certified in radiation oncology and an elected member of the Association of American Physicians, Chan earned his M.D. and Ph.D. in genetics from Johns Hopkins University, where he completed his residency in radiation oncology and a postdoctoral fellowship in the division of tumor biology, according to the release. He has published more than 200 articles in peer-reviewed journals, has made landmark discoveries in his field and has received numerous awards, including the National Cancer Institute Outstanding Investigator Award in 2018, according to the release.

Read more:
Dr. Timothy Chan to lead Cleveland Clinic's new Center for Immunotherapy and Precision Immuno-Oncology - Crain's Cleveland Business

The Regenerative Medicine Market report upholds the future market predictions related to Regenerative Medicine market size, revenue, production, Consumption, gross margin and other substantial factors. Also Regenerative Medicine Market is Segmented Regenerative Medicine Market Share, Size, Trends, & Industry Analysis Report, By Therapy (Tissue engineering, Cell Therapy, Immunotherapy, Gene Therapy); By Products (Acellular Products, Cellular Products); By Application (Oncology, Dermatology, Orthopedic, Cardiology, CNS Disease, Diabetes, Others); By Region: Segment Forecast, 2018 - 2026. It also examines the role of the prominent Regenerative Medicine market players involved in the industry including their corporate overview. While emphasizing the key driving factors for Regenerative Medicine market, the report also offers a full study of the future trends and developments of the market.

The Regenerative Medicine Market is anticipated to reach over USD 79.23 billion by 2026 according to a new research. In 2017, the cell therapy dominated the global Regenerative Medicine market, in terms of revenue. North America is expected to be the leading contributor to the global market revenue in 2017.

The regenerative medicine market is primarily driven by the increasing number of individuals suffering from cancer, rising need to monitor and treating these chronic diseases in the limited time. Furthermore, stringent government policies, proper reimbursement policies, and increasing government healthcare expenditure for developing healthcare infrastructure to also boost the market growth in coming years. Also, rising number of organ transplantation, and increasing number of products in pipeline that are waiting for approval create major opportunity for the regenerative medicines in the coming years. However, some of the ethical and religious concerns for the use of stem cells, and lack of proper regulatory for the approval of various drugs would impede the market growth during the forecast period.

Request Sample Copy of this Report @ https://www.aeresearch.net/request-sample/179813

The key players operating in the Regenerative Medicine market include Organogenesis Inc., Vericel Corporation, Osiris Therapeutics, Inc., Stryker Corporation, and NuVasive, Inc., Medtronic Plc., Acelity, Cook Biotech Inc., Integra LifeSciences, and C.R. Bard. These companies launch new products and collaborate with other market leaders to innovate and launch new products to meet the increasing needs and requirements of consumers.

North America generated the highest revenue in the Regenerative Medicine market in 2017, and is expected to be the leading region globally during the forecast period. Increasing number of patients suffering from chronic diseases, improved healthcare infrastructure and health facilities, accessibility of healthcare facilities, are the primary factors driving the market growth in this region. While, Asia Pacific to be the fastest growing region in the coming years. The growth in this region is majorly attributed to the developing healthcare infrastructure of the countries like India, & China, and rising awareness for the use of regenerative medicines as an effective treatment option for chronic diseases.

Regenerative medicine is a branch of medicine that regrows, and repairs the damaged cells in the human body. These medicines include the use of stem cells, tissue engineering, that further helps in developing new organ that function smoothly. These medicines have the caliber of developing an entire organ as these cells are multipotent. The cells are majorly isolated from bone marrow, and umbilical cord blood.

A Pin-point overview of TOC of Regenerative Medicine Market are:

Overview and Scope of Regenerative Medicine Market

Regenerative Medicine Market Insights

Industry analysis - Porter's Five Force

Company Profiles

Request Customization on This Report @ https://www.aeresearch.net/request-for-customization/179813

See original here:
Regenerative Medicine Market Share Analysis and Research Report by 2025 - News by aeresearch

In the search for improved and high-throughput in vitro models, organoids have emerged as a promising 3D cell culture technology.1 Defined as a three-dimensional multicellular in vitro tissue construct, organoids are derived from cells that spontaneously self-organize into properly differentiated functional cell types to mimic at least some function of an organ.2 Organoid formation is driven by signaling cues in the extracellular matrix and medium, and is influenced by the particular cell types that are present.2 Compared with two-dimensional cultures, organoids incorporate more physiologically relevant cell-cell and cell-matrix interactions, and are a better reflection of the complex network found in vivo.With significant opportunities for studies of human-specific disease mechanisms, personalized medicine, drug discovery, pharmacokinetic profiling and regenerative medicine, organoids are being pursued across a range of disciplines. Many anticipate that these cell culture models will result in more efficient translation of research into clinical success. In this article, we explore the various types of organoids under development and shine a spotlight on some of the different approaches to organoids in cancer research.

Organoids can be derived from pluripotent stem cells (including embryonic stem cells or induced pluripotent stem cells) or neonatal or adult stem cells from healthy or diseased tissue.1,2 Cancer organoids have been generated from a range of human cancer tissues and cell lines including colon, pancreas, prostate, liver, breast, bladder and lung.6-12 This year, a research group led by Hongjun Song, Professor of Neuroscience at the Perelman School of Medicine at the University of Pennsylvania, published a report in Cell detailing methods for the rapid generation of patient-derived glioblastoma organoids.13Fresh tumor specimens were removed from 53 patient cases to produce microdissected tumor pieces that could survive, develop a spherical morphology and continuously grow in culture for at least two weeks (Figure 1). The production of glioblastoma organoids was achieved while maintaining a high level of similarity between the organoids and their parental tumors, with the expression levels of specific markers showing stability over long-term culture (48 weeks). Importantly, native cell-cell interactions were preserved by avoiding mechanical and enzymatic single-cell dissociation of the resected tumor. As Song explains, this was achieved on a clinically relevant timescale: Normally, the treatment for glioblastoma patients starts one month after surgery. The idea is that glioblastoma organoids can be generated within two weeks and subjected to testing of different treatment strategies to come up with the best option for a personalized treatment strategy.

Figure 1: Glioblastoma organoid generation, from fresh tumor pieces to frozen spherical organoids. Image used with permission from Jacob et al. 2020.One concern with organoid formation and expansion is the potential variability of the serum or Matrigel that can exist across batches and sources, creating variable exogenous factors that could cause the organoid to divert. This ultimately compromises reproducibility, a major bottleneck of current organoid systems.2,13 To avoid this source of error, Songs group used an optimized and defined medium devoid of variable factors that could contribute to the clonal selection of specific cell populations in culture.Glioblastoma is the most prevalent primary malignant brain tumor in adults,14 and having glioblastoma organoids available for research would present significant opportunities, explains Song: They can be used to test different drugs based on mutation profiles and to investigate mechanisms underlying tumor progression, drug sensitivity and resistance. While the accuracy of these predictions would need to be verified, researchers hope that patient-derived organoids will be used to help inform oncologists, accelerate drug discovery, and lead to better clinical trial design.Live-Cell Monitoring: Optimizing Workflows for Advanced Cell Models

As cell-based assays become technically more complex, the need to holistically capture dynamic and sometimes subtle cellular events becomes ever more important. By providing real-time imaging data of cellular events without disturbing the sample during the cell culture workflow, live-cell monitoring can support the optimization of these advanced models. Download this whitepaper to discover how live-cell monitoring can support such optimization, with a breadth of applications.

Sponsored Content

For this to be achieved, techniques for the culture and genetic manipulation of primary human hepatocytes need to be refined. This has mostly been pursued through the culture of liver progenitors or fetal hepatocytes, which facilitate studies of liver cancers related to stem cells.16-18 To address the need for organoids derived from functional hepatocytes, researchers across 14 universities, research institutes and hospitals in China and Japan collaborated to genetically engineer reprogrammed human hepatocytes.18 The study, published in Nature Cell Biology, details the successful generation of organoids that represented two major types of liver cancer (hepatocellular carcinoma: HCC and intra-hepatic cholangiocarcinoma: ICC), derived from directly reprogrammed human hepatocytes (hiHeps).Lead author Lulu Sun, of the Shanghai Institute of Biochemistry and Cell Biology at the University of Chinese Academy of Sciences, provides an overview of how the liver cancer organoids were developed: Genomic aberrations begin to occur during cancer initiation, and the normal cells gradually became malignant. We modeled this process by introducing HCC/ICC-related oncogenes into the organoids with a lentivirus. Oncogenes were selected based on their mutation frequency and previous results in animals. Sun notes that gradual changes in cell and organoid morphology were observed in vitro, along with changes in the expression of HCC-related markers, before the organoids were transplanted to inspect their malignancy in vivo: We cultured these organoids in vitro for about two weeks and transplanted them into the liver lobule of immunodeficient mice. Six to eight weeks later, they formed features identical to HCCs.Even though numerous oncogenes have been identified through whole genome sequencing, it has been difficult to determine whether they can drive the initiation of human liver cancers. Ultrastructural analyses revealed that c-Myc, a well-known oncogene, induced HCC-initiation and a unique cellular phenotype in the hiHep organoids. In these cells, mitochondria were in unusually close contact with endoplasmic reticulum membranes. This excessive coupling between mitochondria and the endoplasmic reticulum (referred to as a MAM phenotype) was shown to facilitate HCC-initiation and when blocked, prevented the progression towards HCC, says Sun: Not only were the expression levels of HCC-related genes in organoids reduced, but significantly reduced cancers were formed in mice.Resolving these alterations in mitochondrial organization represents a new potential approach to liver cancer therapies, and possibly others, Sun explains: Restoration of a proper MAM interface may be a useful approach in preventing c-MYC-initiated HCCs. In addition, recently, an increasing number of works captured ultrastructural alterations, including MAMs, in the course of diseases including Alzheimer's disease and fatty liver diseases. Our results showed that the alterations between communications of organelles may also contribute to the cancer initiation process.All About Organoids

Organoids are 3D cell clusters with the structural and functional features of an organ, and can be generated from induced pluripotent stem cells (iPSCs) or adult stem cells acquired from a specific patient. Consequently, organoids make it possible to study the impact of a drug on a specific disease, even a persons own disease they are changing the face of research and medicine as we know it. Download this eBook to discover more about organoids including their analysis and how they are effecting personalized medicine.

Sponsored Content

2. Huch, M., Knoblich, J. A., Lutolf, M. P, et al. (2017). The hope and the hype of organoid research. Development, 144(6), 938941. https://doi.org/10.1242/dev.150201

3. Hutchinson, L., & Kirk, R. (2011). High drug attrition ratesWhere are we going wrong? Nature Reviews Clinical Oncology, 8(4), 189190. https://doi.org/10.1038/nrclinonc.2011.34

4. Fan, H., Demirci, U., Chen, P. (2019). Emerging organoid models: Leaping forward in cancer research. Journal of Hematology & Oncology, 12(142). https://jhoonline.biomedcentral.com/articles/10.1186/s13045-019-0832-4

5. Drost, J., Clevers, H. (2018). Organoids in cancer research. Nature Reviews Cancer, 18(7), 407418. https://doi.org/10.1038/s41568-018-0007-6

6. van de Wetering, M., Francies, H. E., Francis, J. M., et al. (2015). Prospective Derivation of a Living Organoid Biobank of Colorectal Cancer Patients. Cell, 161(4), 933945. https://doi.org/10.1016/j.cell.2015.03.053

7. Boj, S. F., Hwang, C.-I., Baker, L. A., et al. (2015). Organoid Models of Human and Mouse Ductal Pancreatic Cancer. Cell, 160(12), 324338. https://doi.org/10.1016/j.cell.2014.12.021

8. Puca, L., Bareja, R., Prandi, D., et al. (2018). Patient derived organoids to model rare prostate cancer phenotypes. Nature Communications, 9(1), 2404. https://doi.org/10.1038/s41467-018-04495-z

9. Broutier, L., Mastrogiovanni, G., Verstegen, M. M., et al. (2017). Human primary liver cancerderived organoid cultures for disease modeling and drug screening. Nature Medicine, 23(12), 14241435. https://doi.org/10.1038/nm.4438

10. Sachs, N., de Ligt, J., Kopper, O., et al. (2018). A Living Biobank of Breast Cancer Organoids Captures Disease Heterogeneity. Cell, 172(12), 373-386.e10. https://doi.org/10.1016/j.cell.2017.11.010

11. Lee, S. H., Hu, W., Matulay, J. T., et al. (2018). Tumor Evolution and Drug Response in Patient-Derived Organoid Models of Bladder Cancer. Cell, 173(2), 515-528.e17. https://doi.org/10.1016/j.cell.2018.03.017

12. Kim, M., Mun, H., Sung, C. O., et al. (2019). Patient-derived lung cancer organoids as in vitro cancer models for therapeutic screening. Nature Communications, 10(1), 3991. https://doi.org/10.1038/s41467-019-11867-6

13. Jacob, F., Salinas, R. D., Zhang, D. Y., et al. (2020). A Patient-Derived Glioblastoma Organoid Model and Biobank Recapitulates Inter- and Intra-tumoral Heterogeneity. Cell, 180(1), 188-204.e22. https://doi.org/10.1016/j.cell.2019.11.03

14. Ostrom, Q. T., Gittleman, H., Truitt, G., et al. (2018). CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 20112015. Neuro-Oncology, 20(suppl_4), iv1iv86. https://doi.org/10.1093/neuonc/noy131

15. Bruix, J., Han, K.-H., Gores, G., et al. (2015). Liver cancer: Approaching a personalized care. Journal of Hepatology, 62(1), S144S156. https://doi.org/10.1016/j.jhep.2015.02.007

16. Hu, H., Gehart, H., Artegiani, B., et al. (2018). Long-Term Expansion of Functional Mouse and Human Hepatocytes as 3D Organoids. Cell, 175(6), 1591-1606.e19. https://doi.org/10.1016/j.cell.2018.11.013

17. Zhang, K., Zhang, L., Liu, W., et al. (2018). In Vitro Expansion of Primary Human Hepatocytes with Efficient Liver Repopulation Capacity. Cell Stem Cell, 23(6), 806-819.e4. https://doi.org/10.1016/j.stem.2018.10.018

18. Sun, L., Wang, Y., Cen, J., et al, (2019). Modelling liver cancer initiation with organoids derived from directly reprogrammed human hepatocytes. Nature Cell Biology, 21(8), 10151026. https://doi.org/10.1038/s41556-019-0359-5

19. Madhavan, M., Nevin, Z. S., Shick, H. E., et al. (2018). Induction of myelinating oligodendrocytes in human cortical spheroids. Nature Methods, 15(9), 700706. https://doi.org/10.1038/s41592-018-0081-4

20. Post, Y., Puschhof, J., Beumer, J., et al. (2020). Snake Venom Gland Organoids. Cell, 180(2), 233-247.e21. https://doi.org/10.1016/j.cell.2019.11.038

21. Calandrini, C., Schutgens, F., Oka, R., et al. (2020). An organoid biobank for childhood kidney cancers that captures disease and tissue heterogeneity. Nature Communications, 11(1), 1310. https://doi.org/10.1038/s41467-020-15155-6

22. Subramanian, A., Sidhom, E.-H., Emani, M., et al. (2019). Single cell census of human kidney organoids shows reproducibility and diminished off-target cells after transplantation. Nature Communications, 10(1), 5462. https://doi.org/10.1038/s41467-019-13382-0

Read the original post:
Organoids: Exploring Liver Cancer Initiation and the Possibilities of Personalized Glioblastoma Treatment - Technology Networks

Two teams of students from Missouri S&T will compete in the final rounds of the Regnier Venture Creation Challenge 2020, a University of Missouri-Kansas City business plan and pitch competition open to university students in Missouri, Iowa, Kansas and Nebraska.

Missouri S&Ts two teams will compete live virtually in the final round on Friday, May 1, in the Blue KC Healthcare Innovation segment of the competition. So far, the teams have competed against 50 other teams from seven colleges and universities, with projects ranging from medicine to computer science to accounting.

One team is named The GuideLine and is comprised of Deshawn Jones, a senior in biological sciences from Chicago, and David Clausen, a senior in mechanical engineering from Jefferson City, Missouri. The two have created a device to streamline lumbar puncture procedures and reduce the 25 percent of punctures that create potentially severe complications, such as paralysis.

Another team is named Striae Away and is comprised of Nathaniel Blackwell, a senior in biological sciences from St. Louis, and Jessica Crites, a senior in biological sciences from Marthasville, Missouri. Their project uses a bioactive glass composite that could treat pre-existing scars with pregnancy stretch marks as its first market.

The two projects were developed while the students were in a biodesign class taught by Dr. Julie Semon, an assistant professor of biological sciences and director of the Laboratory of Regenerative Medicine at S&T.

For more information about the competition, visit bloch.umkc.edu/entrepreneurship.

See the original post here:
Missouri S&T student teams to compete in regional entrepreneur competition finals - Missouri S&T News and Research

On Monday, the league released its guidelines for how player workouts would resume: no group activities, players arent allowed to use non-NBA workout facilities such as gyms and fitness centers, only four players allowed into practice facilities at one time and no coaches can participate in the workout.

So if the Celtics are able to persuade the Commonwealth of Massachusetts to reopen the Auerbach Center on May 8, they would likely schedule four-player shifts throughout the day for workouts until the league authorizes organized practices. This week, Governor Charlie Baker extended the states stay-at-home order until May 18.

The NBA is making this move because if the season is to resume, players are going to need several weeks to get back into basketball shape.

Another encouraging sign was provided by Rand McClain, a doctor of osteopathic and regenerative medicine in Santa Monica, Calif., who has dealt with professional athletes.

McClain said its possible for the NBA to resume under a controlled environment and with widespread testing of players, team officials, and hotel and arena employees.

I think it all boils down to two things: medically risk assumption, what are you willing to risk? he said. And financially, what do you have on the table? What are you willing to spend? Do you want to curtail the hemorrhaging or take the [financial] loss and go on to next year?

The NBA was the first sports league to stop play after Utah center Rudy Gobert was diagnosed with COVID-19 on March 11. His teammate Donovan Mitchell also tested positive, and a week later, the Celtics Marcus Smart revealed he had the virus. Other NBA players and team employees have also tested positive. The fact that there were several positive tests has made the NBA even more cautious about a resumption.

Commissioner Adam Silver has consulted with medical experts, and the opening of practice facilities is a significant step. But can the NBA really, safely resume?

Its a little more difficult with the NBA because its a contact sport, McClain said. Youre posting up, getting in peoples faces in basketball, so its a little bit different. There are different risks that youre asking the players to assume here. Thats the crux of the matter, are the players willing to assume that [medical] risk? Keeping the fans out of the stadium, thats a no-brainer.

We should have enough testing in place and thats going to need to be part of the program. Testing regularly is important. And then its up to the players to decide, If we all agree, were going to do the regular testing, and we have a relatively clean group and then its a matter of keeping guys from being exposed to the disease during the season.

We should be able to pull it off.

Resuming the NBA would mean a level of isolation for the players. They would have to be kept in controlled environments and tested consistently. Are players willing to make that sacrifice? And what happens if a player tests positive in the middle of the playoffs? Are the games suspended again? Or can that player be removed and treated while other players test again and are cleared to play?

The NBA, as with other professional and college sports leagues, is hoping some testing advancements are made in the next few weeks, which could create a climate in which players and teams feel comfortable with resumption. On Wednesday, National Institute of Allergy and Infectious Diseases director Dr. Anthony Fauci expressed optimism about the antiviral medication remdesivir, which reduced the recovery time from COVID-19 in a recent study.

Hypothetically, the NBA would like to begin clearing teams for practice later this month, and teams could conceivably spend June preparing for a truncated end of the regular season and playoffs in one location. The league would resume in July and conclude in September, trying not to intersect with the NFL opening day or the beginning of college football. That is the ideal plan but the NBA is still in the information-gathering phase on how to approach a return.

Testing is going to be mandatory, McClain said. It will be taking too much risk [if there isnt]. Its going to come back to, Hey guys, you want this to happen, then youre going to have to shell out some coin for the testing. We landed on the moon. We can do this. But at what cost?

Whats evident is that professional sports wont be the same for a while, if ever again. If the NBA is going to be the first league to return, it is going to have to create a safe, structured environment for its players that has never existed for professional athletes.

I cant say the (NBA players) I work with represent everyone, McClain said. But I can say its a cross section when it comes to age and by and large, everyone wants to get back to playing. Everyone says, I want to get back in the game and how do we do this Doc. I think most guys want to get back.

Gary Washburn can be reached at gary.washburn@globe.com. Follow him on Twitter @GwashburnGlobe.

Read more from the original source:
Reopening training facilities is just the beginning of the NBAs risky road back - The Boston Globe

Sore muscles can occur any time you exercise in a new way that your body isn't used to, or when you increase the intensity of your usual workouts.

Here's what you need to know about why your muscles feel sore and how to relieve soreness.

There are two types of muscle soreness: acute and delayed onset.

Acute muscle soreness happens during the activity say if the exercise is too intense or you're using bad form and is an indication you should stop immediately because it could lead to muscle or joint damage, according to the American College of Sports Medicine (ACSM).

Delayed onset muscle soreness (DOMS), on the other hand, sets in about 12 to 24 hours after exercise. It's why you feel so sore the morning after a workout. These sore muscles usually last one to three days, though it can take up to 10 days for soreness to resolve completely. And while DOMS may hurt, it can be helpful for muscle repair.

As you're working out, your muscle fibers may tear slightly. Those tiny muscle tears lead to hypertrophy, which means the muscle cells get bigger, says Julia Iafrate, DO, an assistant professor of rehabilitation and regenerative medicine at Columbia University Medical Center. Once you let the muscle fibers recover, the muscle ends up stronger than it was before.

Just make sure you don't work out those muscles before they're done healing trying to perform intense exercise on sore muscles can result in further pain or even injury.

While there's no way to speed up the body's muscle repair process, you can treat or reduce the symptoms of soreness in a few ways:

You may also be tempted to pop an anti-inflammatory medication like Advil or Aleve until the soreness subsides, but Iafrate warns this could delay muscle repair.

"If the inflammation is too much to bear, then sure, take an Aleve, but it's not something you want to do continuously," she says. "You actually need that inflammation in order to heal."

Run-of-the-mill soreness doesn't warrant a doctor's visit. "But there's a fine line of what's too much soreness," Iafrate says.

Soreness can feel achy, while a muscle strain, which is more serious, may be accompanied by swelling, bruising, and pain, according to Harvard Health.

Iafrate says if your soreness lasts longer than a week, it could indicate something concerning. As long as you have a safe workout regimen, the risk is low for these conditions, but they may occur:

You'll also want to take debilitating pain, swollen limbs, or darker-than-normal urine as a sign to seek medical attention, according to the ACSM. Iafrate suggests seeing a primary care physician or a sports medicine specialist if you're concerned about muscle pain.

Go here to see the original:
How to get rid of sore muscles, and why your muscles get sore - Insider - INSIDER

The Hemolung Respiratory Assist System is a minimally invasive device that does the work of the lungs by removing carbon dioxide directly from the blood.

A device designed at the University of Pittsburgh could help improve outcomes as a treatment for COVID-19 when used in conjunction with non-invasive or mechanical ventilation, and it recentlyreceived Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration. Health records from a New York study showed that close to 90 percent of patients who were placed on mechanical ventilation did not survive. Some intensive care units are now considering mechanical ventilation as a last resort because of the complications and side effects associated with the process, and researchers believe this device could help.

The Hemolung Respiratory Assist System is a minimally invasive device that does the work of the lungs by removing carbon dioxide directly from the blood, much as a dialysis machine does the work of the kidneys. The device was developed by William Federspiel, PhD, professor of bioengineering at Pitts Swanson School of Engineering, and the Pittsburgh-based lung-assist device company ALung Technologies, co-founded by Federspiel.

A public health emergency related to COVID-19 was declared by the Secretary of Health and Human Services on February 4, 2020, and the FDA issued ALung the EUA to treat lung failure caused by the disease. Hemolung could help eliminate damage to the lungs caused by ventilators and does not require intubation or sedation, which allows patients to remain mobile during treatment.

Ventilation can cause serious issues in lungs that are already being damaged by the disease itself, said Federspiel. The Hemolung would allow the lung to rest and heal during the ventilation process by allowing for gentler ventilation. It could also prevent certain patients, who have less severe symptoms, from having to go on ventilation in the first place.

Mechanical ventilation requires patients to be sedated and intubated, and a myriad of complications can arise from the treatment, including collapsed lung, alveolar damage, and ventilator-associated pneumonia. For these more critically ill patients, the Hemolung could be used to help remove CO2, which would allow the mechanical ventilation process to be done more gently.

Before resorting to mechanical ventilation, less severe COVID-19 cases can use non-invasive ventilation, which uses a mask to help support breathing, but sometimes this treatment is not sufficient. In this case, the Hemolung device could be used to support the non-invasive methods and prevent mechanical ventilation altogether.

Peter M. DeComo, Chairman and CEO of ALung Technologies, stated, With published mortality rates as high as 90% for patients receiving invasive mechanical ventilation (IMV), we believe that the Hemolung can be a valuable tool for physicians to be used in conjunction with IMV, by reducing or eliminating the potential of further lung damage caused by high ventilator driving pressures, often referred to as Ventilator Induced Lung Injury. Many of the academic medical centers involved with our clinical trial have already requested the use of the Hemolung RAS for treatment of their COVID-19 patients.

Created to help chronic obstructive pulmonary disease (COPD) and acute respiratory distress syndrome (ARDS) patients, Hemolung has already been used on thousands of patients in Europe, where it was approved in 2013, and it is currently in clinical trials in the United States.

Since the onset of the pandemic, the device has been used on some COVID-19 patients with success; however, set-up of the Hemolung is not trivial. Medical professionals would need to be trained to use the technology, and it would take time to supply a significant number of devices.

Federspiel also holds appointments in the School of Medicine and the McGowan Institute for Regenerative Medicine (MIRM) at Pitt and is a Fellow of the National Academy of Inventors.

This technology developed by Dr. Federspiel and ALung Technologies is a perfect example of how collaborative research at the McGowan Institute can impact human lives, said William Wagner, director of MIRM and professor of surgery, bioengineering and chemical engineering at Pitt. A clinical viewpoint is necessary, but medical training doesnt give you an engineers perspective of design and manufacturing. You need a solid foot in both camps to make progress.

The rest is here:
Giving Distressed Lungs a Safer Fighting Chance - Global Health News Wire

EIB, kENUP Foundation and Pluristem Will Host Investor & Analyst Call

HAIFA, Israel, April 27, 2020 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing a platform of novel biological therapeutic products, cordially invites investors, the media, and the public to join a signing ceremony and analyst & investor call on Thursday, April 30, 2020.

Signing Ceremony: 10:00h CEST / 11:00 IDT/ 4:00 am EDT

Signing of a Memorandum of Understanding on Bio-Convergence in Health between the European Investment Bank and Israel Innovation Authority of the State of Israel

&

Signing of Finance Contract on Innovation Cell Therapies (EGFF) between the European Investment Bank and Pluristem.

Bio-Convergence Health is a collaboration between Israel and Europe to advance technological and investment alliances.

As previously announced, the European Investment Bank is providing a 50 million non-dilutive financing to Pluristem in support of the Companys research and development in the EU to further advance its regenerative cell therapy platform, and to assist moving the products in its pipeline to market, with a special focus on clinical development of PLX cells as a treatment for complications associated with COVID-19.

The half-hour signing ceremony will be live streamed at: https://signing-ceremony.eu/

Investor & Analyst Call: 15:00h CEST / 16:00h IDT / 09:00 am EDTThe European Investment Bank, kENUP Foundation and Pluristem will conduct a call to discuss the 50 million financing. Analysts are invited to ask questions during the Q&A session. The public is invited to listen to the call at: https://signing-ceremony.eu/

About the European Investment BankThe European Investment Bank (EIB) is the long-term lending institution of the European Union, owned by its Member States. It makes long-term finance available for sound investment in order to contribute towards EU policy goals.

Investment Plan for EuropeThe Investment Plan for Europe (the Juncker Plan) is one of the EU's key actions to boost investment in Europe, thereby creating jobs and fostering growth. To this end, smarter use will be made of new and existing financial resources. The EIB Group, consisting of the European Investment Bank and the European Investment Fund, is playing a vital role in this investment plan. With guarantees from the European Fund for Strategic Investments (EFSI), the EIB and EIF are able to take on a higher share of project risk, encouraging private investors to participate in the projects. In addition to EFSI, the new European Investment Advisory Hub (EIAH) helps public and private sector project promoters to structure investment projects more professionally. The projects and agreements approved under EFSI (European Fund for Strategic Investments) so far are expected to mobilise almost 466 billion of investments and will benefit over 1 million start-ups and SMEs (Small Medium Enterprises) in the 27 Member States.

About kENUP FoundationkENUP is a global partnership in innovation, promoting research based innovation for Europe with public and societal benefit. kENUP develops projects to pursue market-leading positions for European innovation businesses. In this capacity, kENUP is supporting the execution of the European Fund for Strategic Investments (EFSI, the so-called Juncker Plan), alongside its successor EFSI 2.0 and of the current InvestEU Fund. kENUP is a not-for-profit organization established as a foundation in the Republic of Malta by Public Deed on November 6, 2014. kENUPs activities are published in the European Transparency Register.

About Pluristem TherapeuticsPluristem Therapeutics Inc. is a leading regenerative medicine company developing novel placenta-based cell therapy product candidates. The Company has reported robust clinical trial data in multiple indications for its patented PLX cell product candidates and is currently conducting late stage clinical trials in several indications. PLX cell product candidates are believed to release a range of therapeutic proteins in response to inflammation, ischemia, muscle trauma, hematological disorders and radiation damage. The cells are grown using the Company's proprietary three-dimensional expansion technology and can be administered to patients off-the-shelf, without tissue matching. Pluristem has a strong intellectual property position; a Company-owned and operated GMP-certified manufacturing and research facility; strategic relationships with major research institutions; and a seasoned management team.

Safe Harbor StatementThis press release contains express or implied forward-looking statements within the Private Securities Litigation Reform Act of 1995 and other U.S. Federal securities laws. For example, Pluristem is using forward-looking statements when it discusses its expectation to receive the financing from the EIB, the belief that the financing will support its research and development in the EU to further advance its regenerative cell therapy platform, to assist moving the products in its pipeline to market, with a special focus on clinical development of PLX cells as a treatment for complications associated with COVID-19. These forward-looking statements and their implications are based on the current expectations of the management of Pluristem only, and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in technology and market requirements; Pluristem may encounter delays or obstacles in launching and/or successfully completing its clinical trials; Pluristems products may not be approved by regulatory agencies, Pluristems technology may not be validated as it progresses further and its methods may not be accepted by the scientific community; Pluristem may be unable to retain or attract key employees whose knowledge is essential to the development of its products; unforeseen scientific difficulties may develop with Pluristems process; Pluristems products may wind up being more expensive than it anticipates; results in the laboratory may not translate to equally good results in real clinical settings; results of preclinical studies may not correlate with the results of human clinical trials; Pluristems patents may not be sufficient; Pluristems products may harm recipients; changes in legislation may adversely impact Pluristem; inability to timely develop and introduce new technologies, products and applications; loss of market share and pressure on pricing resulting from competition, which could cause the actual results or performance of Pluristem to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law, Pluristem undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. For a more detailed description of the risks and uncertainties affecting Pluristem, reference is made to Pluristem's reports filed from time to time with the Securities and Exchange Commission.

Contact:Dana RubinDirector of Investor Relations972-74-7107194danar@pluristem.com

Here is the original post:
The European Investment Bank (EIB), EU Delegation to Israel, the Israel Innovation Authority, and Pluristem Cordially Invite the Public to an Online...

Timothy Chan, M.D., Ph.D.

Timothy Chan, M.D., Ph.D., has been appointed director of the Center for Immunotherapy and Precision Immuno-Oncology at Cleveland Clinic.

A renowned immuno-oncology and cancer genomics expert, Dr. Chan leads the new center which brings together multidisciplinary experts from across the Cleveland Clinic enterprise to advance research and treatment related to the rapidly growing field of immuno-oncology.

The center will comprise four arms, including a Cleveland cell therapy program in collaboration with the Case Comprehensive Cancer Center, and will recruit national and international experts in computational science, immunotherapy and cancer immunology. The new center will initially have sites in Cleveland and the soon-to-open Cleveland Clinic Florida Research and Innovation Center in Port St. Lucie, Florida, both focused on immunotherapy research and developmental therapeutics.

Dr. Chan will also collaborate with experts in the new Center for Global and Emerging Pathogens Research, which is focused on broadening understanding of immunology and microbial pathogenesis with the goal of improving treatment for a variety of diseases, including virus-induced cancers.

Immunotherapy is the future of research in cancer and various other diseases and Cleveland Clinic has made it a priority by establishing this new center, said Serpil Erzurum, M.D., chair of Cleveland Clinics Lerner Research Institute. The Center for Immunotherapy and Precision Immuno-Oncology will empower clinicians and scientists throughout the enterprise to advance personalized cancer care and breakthrough immunotherapy research at Cleveland Clinic.

Dr. Chan joins Cleveland Clinic from Memorial Sloan Kettering Cancer Center and Weill Cornell School of Medicine, where he leads the Immunogenomics and Precision Oncology Platform and was a tenured professor, the PaineWebber Chair, and the Translational Oncology Division chair. He is an internationally recognized expert in precision immuno-oncology and a pioneer in using genomics to determine which patients will respond best to certain types of immunotherapies. He has published over 200 articles in peer-reviewed journals, has made landmark discoveries in his field, and has received numerous awards, including the National Cancer Institute Outstanding Investigator Award in 2018.

Innovation in precision immunotherapy is one of the most exciting areas in cancer research, said Brian Bolwell, M.D., chairman of Taussig Cancer Institute, Cleveland Clinic Cancer Center. The addition of Dr. Chan, a pioneer in cancer genomics, and the new centers focus on research and clinical trials will strengthen our ability to provide advanced treatment options for our patients.

Dr. Chan also joins the leadership of the National Center for Regenerative Medicine of Case Western Reserve University. Dr. Chan is also on staff in the Genomic Medicine Institute of the Lerner Research Institute; and the Department of Radiation Oncology of the Taussig Cancer Institute.

Dr. Chan earned his M.D. and Ph.D. in genetics from Johns Hopkins University, where he also completed a residency in radiation oncology and a postdoctoral fellowship in the division of tumor biology. He is board certified in radiation oncology and is an elected member of the Association of American Physicians (AAP).

See the original post here:
Cleveland Clinic Appoints Timothy Chan, M.D., Ph.D., as Director of Center for Immunotherapy and Precision Immuno-Oncology - Health Essentials from...